Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.

@article{Mehta2010AlternatedayMA,
  title={Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.},
  author={Parinda A Mehta and A. A. T. M. M. Vinks and Alexandra H. Filipovich and Jack Jan Hendrik Bleesing and Sonata Jodele and Michael B. Jordan and Rebecca A Marsh and Richard Tarin and Stephanie Edwards and Deborah Fearing and Julia Lawrence and Stella M. Davies},
  journal={Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation},
  year={2010},
  volume={16 10},
  pages={1458-62}
}
Disseminated fungal infection is a major cause of morbidity and mortality in children undergoing hematopoietic stem cell transplantation (HSCT). Prophylaxis with amphotericin B can be limited by renal toxicity. Oral triazoles can be limited by poor absorption, large interindividual pharmacokinetic (PK) variability, and hepatic toxicity, leading to interruptions in therapy and breakthrough infections. Intravenous (i.v.) micafungin has potential advantages, because of its better safety profile… CONTINUE READING
14 Extracted Citations
29 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 14 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 29 references

Susceptibility of micafungin in Candida strains isolated from patients with invasive Candida infections by EUCAST methodology

  • JW GEMouton, I Curfs-Breuker, CH Klaassen, JF. Meis
  • Trends in Medical Mycology,
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…